In support, we have shown that our HER3-homing protein construct, HPK, mediates the targeted delivery of chemotherapeutic compounds to trastuzumab (Herceptin)-resistant breast tumors, which display high cell surface densities of HER3 (21). The gene discussed is ERBB3; the disease is breast neoplasm.